MedTrace Logo

Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention

NCT04304053 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2300

Last updated 2020-06-30

No results posted yet for this study

Summary

This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).

Conditions

Interventions

DRUG

Treatment and prophylaxis

Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7 Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.

OTHER

Standard Public Health measures

Isolation of patient and contact tracing as per national guidelines.

Sponsors & Collaborators

  • Germans Trias i Pujol Hospital

    collaborator OTHER

  • Department of Health, Generalitat de Catalunya

    collaborator OTHER_GOV

  • Laboratorios Gebro Pharma SA

    collaborator UNKNOWN

  • Laboratorios Rubió

    collaborator UNKNOWN

  • Institut Catala de Salut

    collaborator OTHER_GOV

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-18
Primary Completion
2020-06-15
Completion
2020-06-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04304053 on ClinicalTrials.gov